Display options
Cite
Michels J, Becker N, Suciu S, et al. Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial. Oncoimmunology. 2018;7(6):e1428157doi: 10.1080/2162402X.2018.1428157.
Michels, J., Becker, N., Suciu, S., Kaiser, I., Benner, A., Kosaloglu-Yalcin, Z., Agoussi, S., Halama, N., Pawlita, M., Waterboer, T., Eichmüller, S. B., Jäger, D., Eggermont, A. M. M., & Zörnig, I. (2018). Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial. Oncoimmunology, 7(6), e1428157. https://doi.org/10.1080/2162402X.2018.1428157
Michels, Judith, et al. "Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial." Oncoimmunology vol. 7,6 (2018): e1428157. doi: https://doi.org/10.1080/2162402X.2018.1428157
Michels J, Becker N, Suciu S, Kaiser I, Benner A, Kosaloglu-Yalcin Z, Agoussi S, Halama N, Pawlita M, Waterboer T, Eichmüller SB, Jäger D, Eggermont AMM, Zörnig I. Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial. Oncoimmunology. 2018 Feb 12;7(6):e1428157. doi: 10.1080/2162402X.2018.1428157. eCollection 2018. PMID: 29872552; PMCID: PMC5980408.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2018 Feb 12;7(6):e1428157. doi: 10.1080/2162402X.2018.1428157. eCollection 2018.

Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial.

Oncoimmunology

Judith Michels, Natalia Becker, Stefan Suciu, Iris Kaiser, Axel Benner, Zeynep Kosaloglu-Yalcin, Sandrine Agoussi, Niels Halama, Michael Pawlita, Tim Waterboer, Stefan B Eichmüller, Dirk Jäger, Alexander M M Eggermont, Inka Zörnig

Affiliations

  1. Department of Medical Oncology, Gustave Roussy Comprehensive Cancer Center, Villejuif/Paris-Sud, France.
  2. Université Paris-Sud, Kremlin Bicêtre, Paris, France.
  3. Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  4. European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
  5. Department of Medical Oncology, National Center for Tumor Diseases, Internal Medicine VI, Heidelberg University Hospital, Heidelberg, Germany.
  6. Clincial Cooperation Unit "Applied Tumor Immunity", German Cancer Research Center (DKFZ), Heidelberg, Germany.
  7. INSERM U981, Gustave Roussy Comprehensive Cancer Center, Villejuif/Paris-Sud, France.
  8. Division of Molecular Diagnostics of Oncogenic Infections, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  9. GMP & T Cell Therapy Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.

PMID: 29872552 PMCID: PMC5980408 DOI: 10.1080/2162402X.2018.1428157

[No abstract available.]

Keywords: autoantibody; ganglioside; melanoma; multiplex serology; rhodopsin

References

  1. J Immunol. 2004 Mar 15;172(6):3480-90 - PubMed
  2. Cancer Immunol Immunother. 2007 Jan;56(1):110-6 - PubMed
  3. Cell. 2016 Mar 10;164(6):1233-1247 - PubMed
  4. Sci Transl Med. 2016 Mar 2;8(328):328rv4 - PubMed
  5. Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):4968-73 - PubMed
  6. J Exp Med. 1980 Nov 1;152(5):1184-93 - PubMed
  7. Clin Exp Immunol. 2002 Dec;130(3):441-8 - PubMed
  8. Science. 2015 Apr 3;348(6230):124-8 - PubMed
  9. N Engl J Med. 2014 Feb 13;370(7):599-609 - PubMed
  10. Int J Cancer. 2007 Mar 15;120(6):1268-76 - PubMed
  11. Nat Commun. 2016 Oct 03;7:12832 - PubMed
  12. Int J Cancer. 1993 Feb 20;53(4):566-73 - PubMed
  13. N Engl J Med. 2006 Sep 28;355(13):1307-17 - PubMed
  14. Int J Cancer. 2015 Jan 1;136(1):138-51 - PubMed
  15. Tumour Biol. 2016 Jul;37(7):9899-907 - PubMed
  16. J Exp Med. 1980 Nov 1;152(5):1175-83 - PubMed
  17. Clin Chem. 2005 Oct;51(10):1845-53 - PubMed
  18. J Clin Invest. 1999 Sep;104(6):769-76 - PubMed
  19. Biometrics. 1991 Sep;47(3):825-39 - PubMed
  20. Cancer Res. 1999 Oct 15;59(20):5392-7 - PubMed
  21. BMC Cancer. 2011 May 27;11:203 - PubMed
  22. Cancer Immunol Immunother. 2015 Nov;64(11):1369-81 - PubMed
  23. Cancer Res. 1992 Sep 15;52(18):4948-53 - PubMed
  24. N Engl J Med. 2014 Dec 4;371(23 ):2189-2199 - PubMed
  25. J Biol Chem. 2007 Mar 16;282(11):8123-33 - PubMed
  26. J Immunol. 1996 Nov 15;157(10):4333-40 - PubMed
  27. FEBS Lett. 2004 Jun 4;567(2-3):203-8 - PubMed
  28. Mol Cancer Res. 2008 Jan;6(1):110-8 - PubMed
  29. Nat Med. 2015 Jan;21(1):81-5 - PubMed
  30. Nat Med. 2013 Jun;19(6):747-52 - PubMed
  31. Clin Cancer Res. 2000 Mar;6(3):874-9 - PubMed
  32. Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1925-30 - PubMed
  33. Cancer Res. 2006 Jul 1;66(13):6816-25 - PubMed
  34. J Clin Oncol. 2013 Oct 20;31(30):3831-7 - PubMed
  35. Nat Rev Cancer. 2014 Feb;14(2):135-46 - PubMed
  36. Science. 2015 Oct 9;350(6257):207-211 - PubMed
  37. J Clin Oncol. 2013 Nov 10;31(32):e439-42 - PubMed
  38. J Clin Oncol. 2009 Dec 20;27(36):6199-206 - PubMed
  39. Cancer Cell. 2013 May 13;23 (5):618-33 - PubMed
  40. J Clin Pathol. 2001 Mar;54(3):229-35 - PubMed
  41. J Clin Oncol. 1994 May;12(5):1036-44 - PubMed
  42. Sci Transl Med. 2015 Jan 21;7(271):271ps1 - PubMed
  43. Nature. 2014 Nov 27;515(7528):577-81 - PubMed
  44. J Clin Oncol. 2001 May 1;19(9):2370-80 - PubMed
  45. Int J Cancer. 2005 Mar 10;114(1):88-93 - PubMed
  46. N Engl J Med. 2015 Jun 25;372(26):2509-20 - PubMed
  47. Cancer Res. 1996 Jun 15;56(12):2844-8 - PubMed
  48. Nature. 2016 Aug 4;536(7614):91-5 - PubMed
  49. J Natl Cancer Inst. 1987 Jan;78(1):55-60 - PubMed

Publication Types